Edition:
India

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

26.56USD
26 Apr 2018
Change (% chg)

$1.39 (+5.52%)
Prev Close
$25.17
Open
$25.11
Day's High
$26.67
Day's Low
$25.11
Volume
185,890
Avg. Vol
276,412
52-wk High
$32.22
52-wk Low
$16.51

Chart for

About

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $954.94
Shares Outstanding(Mil.): 31.91
Dividend: --
Yield (%): --

Financials

BRIEF-Flexion Therapeutics Reports Q4 Sales $355,000

* FLEXION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

09 Mar 2018

BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta

* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)

08 Jan 2018

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

08 Dec 2017

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

07 Nov 2017

Earnings vs. Estimates